Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3394 - Efficacy and safety data in elderly patients (pts) with metastatic renal cell carcinoma (mRCC) included in the nivolumab Expanded Access Program (EAP) in Italy


10 Sep 2017


Poster display session


Geriatric Oncology;  Immunotherapy;  Renal Cell Cancer


roberto sabbatini


Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371


R. sabbatini1, L. Galli2, S. Pignata3, G. Lo Re4, F. Valcamonico5, C. Defferrari6, M. Spada7, D. Santini8, C. Masini9, L. Ciuffreda10, E.M. Ruggeri11, A. Chioni12, L. Livi13, D. Fagnani14, A. Bonetti15, L. Giustini16, S. Duranti17, G. Procopio18, C. Caserta19, G. Cartenì20

Author affiliations

  • 1 Oncology, AOU Policlinico, 41100 - Modena/IT
  • 2 Oncology, AOU Pisana Istituto Toscano Tumori, Pisa/IT
  • 3 Irccs, Fondazione G. Pascale, 80131 - Napoli/IT
  • 4 Ao, Santa Maria degli Angeli, 41125 - Pordenone/IT
  • 5 Asst, Spedali Civili di Brescia, Brescia/IT
  • 6 Oncology, Ospedali Galliera, Genova/IT
  • 7 Oncology, Fondazione Istituto Giglio, Cefalù/IT
  • 8 Oncology, Campus Bio-Medico, 128 - Roma/IT
  • 9 Irccs, AO Arcispedale Santa Maria Nuova, 42100 - Reggio Emilia/IT
  • 10 Oncology, Città della salute e della Scienza, Torino/IT
  • 11 Oncology, Ospedale Belcolle, Viterbo/IT
  • 12 Oncology, USL 9 Presidio Ospedaliero Misericordia, Grosseto/IT
  • 13 Radiotherapy, AOU Careggi, Firenze/IT
  • 14 Oncology, ASST, Vimercate/IT
  • 15 Oncology, Ospedale Mater Salutis, 37045 - Legnago/IT
  • 16 Uoc, Oncologia Area Vasta 4, Fermo/IT
  • 17 Oncology, Azienda ASL8, Arezzo/IT
  • 18 Fondazione Irccs, Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 19 Oncology, AO S.ta Maria, 5100 - Terni/IT
  • 20 Oncology, A.O. A. Cardarelli, 80131 - Napoli/IT


Abstract 3394


The risk of developing renal cell carcinoma (RCC) increases with age, and given the constant gain in life expectancy of the general population, RCC is frequently observed in the elderly. More than 80% of cancer pts aged ≥ 70 years have at least one comorbidity requiring treatment, leaving them exposed to drug interactions. Due to high frequency of comorbidities, these pts are often under-represented in clinical trials. The purpose of this analysis is to evaluate the feasibility of treatment with nivolumab in the elderly (≥ 70 years) and very elderly (≥ 75 years) in the EAP in Italy, given a more realistic picture of real world setting.


Nivolumab was available upon physician request for pts aged ≥18 years who had relapsed after at least one prior systemic treatment in the advanced or metastatic setting. Nivolumab 3 mg/kg was administered intravenously every 2 weeks to a maximum of 24 months. Pts included in the analysis had received ≥ 1 dose of nivolumab and were monitored for adverse events (AEs) using Common Terminology Criteria for Adverse Events.


Of 389 Italian pts with mRCC enrolled in the EAP in Italy 125 pts (32%) had ≥70 years and 70 (18%) had ≥75 years. With a median follow-up of 9.8 months (0.1-16.2) in the elderly population (≥70 years), the disease control rate (DCR) was 58% including 1 patient in complete response (CR), 32 pts in partial response (PR) and 40 patients in stable disease (SD). Regarding the very elderly population (≥75 years), with a median follow-up of 9.8 months (0.1 -14.9), the DCR was 60% including 1 patient with CR, 19 pts with PR and 22 with SD. As of May 2017, 6 and 12 months overall survival (OS) rate were 87.2% and 77.8% respectively in the elderly population. Regarding the very elderly, the 6 and 12 months OS rate was 83.6% and 77.7%, respectively. The safety profile was consistent to what already observed in the general population.


These results suggest that elderly population can benefit from nivolumab treatment with safety results consistent to what previously reported, supporting the use of nivolumab in this subpopulation.

Clinical trial identification


Legal entity responsible for the study

Sergio Bracarda coordinator Italian RCC EAP Group




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.